Update in Infectious Diseases in Liver Transplant Recipients

Clinics in Liver Disease

Volumn 11, Issue 2, 2007, Pages 337-354

  Huprikar, Shirish ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; GANCICLOVIR; LYMPHOCYTE ANTIBODY; PYRROLE DERIVATIVE; RAPAMYCIN; TACROLIMUS; VALGANCICLOVIR; VORICONAZOLE;

ANTIBIOTIC THERAPY; ASPERGILLOSIS; ASPERGILLUS; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BILOMA; CATHETER INFECTION; CLINICAL TRIAL; COLITIS; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEVER; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INVASIVE CANDIDIASIS; KIDNEY FAILURE; LABORATORY TEST; LIVER GRAFT; LUNG ASPERGILLOSIS; META ANALYSIS; MORTALITY; MYCOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT CARE; PERCUTANEOUS DRAINAGE; PERITONITIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; REVIEW; SEPSIS; SURGICAL INFECTION; SYSTEMATIC REVIEW; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; VIRUS INFECTION;

BACTERIAL INFECTIONS; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; MYCOSES; VIRUS DISEASES;

EID: 34347208636     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.04.006     Document Type: Review

References (72)

1. Snydman D.R. Infection in solid organ transplantation. Transpl Infect Dis 1 1 (1999) 21-28
2. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 338 24 (1998) 1741-1751
3. Singh N. The current management of infectious diseases in the liver transplant recipient. Clin Liver Dis 4 3 (2000) 657-673 ix
4. Blair J.E., and Kusne S. Bacterial, mycobacterial, and protozoal infections after liver transplantation-part I. Liver Transpl 11 12 (2005) 1452-1459
5. Kusne S., and Blair J.E. Viral and fungal infections after liver transplantation-part II. Liver Transpl 12 1 (2006) 2-11
6. Kroger A.T., Atkinson W.L., Marcuse E.K., et al. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-15 (2006) 1-48
7. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 4 Suppl 10 (2004) 160-163
8. Safdar N., Said A., Lucey M.R., et al. Infected bilomas in liver transplant recipients: clinical features, optimal management, and risk factors for mortality. Clin Infect Dis 39 4 (2004) 517-525
9. Said A., Safdar N., Lucey M.R., et al. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. Am J Transplant 4 4 (2004) 574-582
10. Pungpapong S., Alvarez S., Hellinger W.C., et al. Peritonitis after liver transplantation: incidence, risk factors, microbiology profiles, and outcome. Liver Transpl 12 8 (2006) 1244-1252
11. Tollemar J., Ericzon B.G., Barkholt L., et al. Risk factors for deep Candida infections in liver transplant recipients. Transplant Proc 22 4 (1990) 1826-1827
12. Collins L.A., Samore M.H., Roberts M.S., et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 170 3 (1994) 644-652
13. Patel R., Portela D., Badley A.D., et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 62 7 (1996) 926-934
14. Husain S., Tollemar J., Dominguez E.A., et al. Changes in the spectrum and risk factors for invasive candidiasis in liver transplant recipients: prospective, multicenter, case-controlled study. Transplantation 75 12 (2003) 2023-2029
15. Pfaller M.A., Diekema D.J., Jones R.N., et al. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbiol 40 3 (2002) 852-856
16. Mora-Duarte J., Betts R., Rotstein C., et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347 25 (2002) 2020-2029
17. Magill S.S., Shields C., Sears C.L., et al. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 44 2 (2006) 529-535
18. Panackal A.A., Gribskov J.L., Staab J.F., et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 44 5 (2006) 1740-1743
19. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 31 2 (2000) 545-553
20. Winston D.J., Pakrasi A., and Busuttil R.W. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 131 10 (1999) 729-737
21. Cruciani M., Mengoli C., Malena M., et al. Antifungal prophylaxis in liver transplant patients: a systematic review and meta-analysis. Liver Transpl 12 5 (2006) 850-858
22. Singh N., and Paterson D.L. Aspergillus infections in transplant recipients. Clin Microbiol Rev 18 1 (2005) 44-69
23. Singh N., Avery R.K., Munoz P., et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 36 1 (2003) 46-52
24. Singh N., Arnow P.M., Bonham A., et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 64 5 (1997) 716-720
25. Fortun J., Martin-Davila P., Moreno S., et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 8 11 (2002) 1065-1070
26. Gavalda J., Len O., San Juan R., et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 41 1 (2005) 52-59
27. Singh N., Limaye A.P., Forrest G., et al. Late-onset invasive aspergillosis in organ transplant recipients in the current era. Med Mycol 44 5 (2006) 445-449
28. Paterson D.L., and Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 78 2 (1999) 123-138
29. Ascioglu S., Rex J.H., de Pauw B., et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34 1 (2002) 7-14
30. Kwak E.J., Husain S., Obman A., et al. Efficacy of galactomannan antigen in the Platelia Aspergillus enzyme immunoassay for diagnosis of invasive aspergillosis in liver transplant recipients. J Clin Microbiol 42 1 (2004) 435-438
31. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347 6 (2002) 408-415
32. Meletiadis J., Petraitis V., Petraitiene R., et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis 194 7 (2006) 1008-1018
33. Singh N., Limaye A.P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81 3 (2006) 320-326
34. Singh N., Paterson D.L., Gayowski T., et al. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 71 7 (2001) 910-913
35. Fortun J., Martin-Davila P., Moreno S., et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother 52 5 (2003) 813-819
36. Biancofiore G., Bindi M.L., Baldassarri R., et al. Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study. Transpl Int 15 7 (2002) 341-347
37. Forman L.M., Lewis J.D., Berlin J.A., et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 122 4 (2002) 889-896
38. O'Grady J.G., Smith H.M., Davies S.E., et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 14 1 (1992) 104-111
39. Ljungman P., Griffiths P., and Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34 8 (2002) 1094-1097
40. Cytomegalovirus. Am J Transplant 4 Suppl 10 (2004) 51-58
41. Kalil A.C., Levitsky J., Lyden E., et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143 12 (2005) 870-880
42. Gane E., Saliba F., Valdecasas G.J., et al. Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. [corrected]. Lancet 350 9093 (1997) 1729-1733
43. Winston D.J., and Busuttil R.W. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 75 2 (2003) 229-233
44. Winston D.J., and Busuttil R.W. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir. Guidelines for vaccination of solid organ transplant candidates and recipients for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors. Transplantation 77 2 (2004) 305-308
45. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4 4 (2004) 611-620
46. Jain A., Orloff M., Kashyap R., et al. Does valganciclovir hydrochloride (Valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?. Transplant Proc 37 7 (2005) 3182-3186
47. Park J.M., Lake K.D., Arenas J.D., et al. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 12 1 (2006) 112-116
48. Singh N., Yu V.L., Mieles L., et al. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 120 5 (1994) 375-381
49. Singh N., Paterson D.L., Gayowski T., et al. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, controlled trial. Transplantation 70 5 (2000) 717-722
50. Daly J.S., Kopasz A., Anandakrishnan R., et al. Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients. Am J Transplant 2 10 (2002) 955-958
51. Paya C.V., Wilson J.A., Espy M.J., et al. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J Infect Dis 185 7 (2002) 854-860
52. Torre-Cisneros J., Madueno J.A., Herrero C., et al. Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. Clin Microbiol Infect 8 12 (2002) 773-780
53. Singh N., Wannstedt C., Keyes L., et al. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. Transplantation 79 1 (2005) 85-90
54. Small L.N., Lau J., and Snydman D.R. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 43 7 (2006) 869-880
55. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 40 5 (2005) 704-708
56. Snydman D.R. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants: the case for prophylaxis. Clin Infect Dis 40 5 (2005) 709-712
57. Kusne S., Grossi P., Irish W., et al. Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 68 8 (1999) 1125-1131
58. Limaye A.P., Bakthavatsalam R., Kim H.W., et al. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 78 9 (2004) 1390-1396
59. Razonable R.R., Rivero A., Rodriguez A., et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 184 11 (2001) 1461-1464
60. Humar A., Mazzulli T., Moussa G., et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 5 5 (2005) 1065-1070
61. Humar A., Paya C., Pescovitz M.D., et al. Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 4 4 (2004) 644-649
62. Humar A., Kumar D., Boivin G., et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 186 6 (2002) 829-833
63. Martin D.F., Sierra-Madero J., Walmsley S., et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 346 15 (2002) 1119-1126
64. Babel N., Gabdrakhmanova L., Juergensen J.S., et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. Transplantation 78 2 (2004) 283-285
65. Fellay J., Venetz J.P., Aubert J.D., et al. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Transplant Proc 37 2 (2005) 949-951
66. El Sayegh S., Keller M.J., Huprikar S., et al. Solid organ transplantation in HIV-infected recipients. Pediatr Transplant 8 3 (2004) 214-221
67. Palella Jr. F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 13 (1998) 853-860
68. Roland M.E., and Stock P.G. Liver transplantation in HIV-infected recipients. Semin Liver Dis 26 3 (2006) 273-284
69. Ragni M.V., Belle S.H., Im K., et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 188 10 (2003) 1412-1420
70. de Vera M.E., Dvorchik I., Tom K., et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent Hepatitis C. Am J Transplant 6 12 (2006) 2983-2993
71. Frassetto L., Baluom M., Jacobsen W., et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 80 1 (2005) 13-17
72. Norris S., Taylor C., Muiesan P., et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 10 10 (2004) 1271-1278